Categories
Change Password!
Reset Password!
Elobixibat is a triple-action laxative that enhances water secretion, promotes colonic motility, and restores the desire to defecate. This single-center, retrospective observational study sought to explore its efficiency and safety in chronic constipation patients who were resistant to conventional treatments.
In people with chronic constipation refractory to other laxatives, two-week Elobixibat treatment significantly improves stool consistency, abdominal symptoms, and frequency of bowel movement. Moreover, it is well-tolerated with minimal adverse events.
Elobixibat is a triple-action laxative that enhances water secretion, promotes colonic motility, and restores the desire to defecate. This single-center, retrospective observational study sought to explore its efficiency and safety in chronic constipation patients who were resistant to conventional treatments.
Volunteers (age 18 years and above) diagnosed with refractory chronic constipation based on the Rome IV criteria were enrolled. Data on spontaneous bowel movements, Bristol stool form scale (BSFS) scores, abdominal symptoms, and adverse events were collected for patients treated with Elobixibat.
Overall, 311 patients were examined. After two weeks of Elobixibat use, spontaneous bowel movements markedly raised from 2.9 ± 1.9 to 4.3 ± 1.9 times per week (Figure 1), and BSFS scores improved from 3.2 ± 1.7 to 4.4 ± 1.4.
There was a notable drop in the proportion of patients with hard stools and an increase in those with normal stools. Remarkable improvements were also observed in abdominal symptoms, such as difficulty defecating, abdominal pain and distention, feeling of incomplete stool passage, and straining. Notably, 43.9% of patients discontinued their previous laxatives after starting Elobixibat, which was well-tolerated with few adverse events reported.
Elobixibat demonstrated potency in alleviating chronic constipation in patients resistant to other laxatives, regardless of prior treatments or patient characteristics. By serving as a single-action laxative, Elobixibat may aid in reducing polypharmacy.
JGH Open
Efficacy and safety of elobixibat in combination with or switched from conventional treatments of chronic constipation: A retrospective observational study
Takaaki Eguchi et. al.
Comments (0)